Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-07-04
2006-07-04
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S253010
Reexamination Certificate
active
07071335
ABSTRACT:
A Compound of formula(wherein X is O or S and R1–R5are disclosed herein) or a pharmaceutically acceptable salt thereof (each being a “Piperazine Compound”), pharmaceutical compositions comprising a Piperazine Compound and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.
REFERENCES:
patent: 4439606 (1984-03-01), De et al.
patent: 4450272 (1984-05-01), Du et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5430033 (1995-07-01), Cliffe et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5461047 (1995-10-01), Hansen, Jr. et al.
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5762925 (1998-06-01), Sagen
patent: 5780472 (1998-07-01), Cho et al.
patent: 5789412 (1998-08-01), Halazy et al.
patent: 5792768 (1998-08-01), Kulagowski et al.
patent: 5922872 (1999-07-01), Cook et al.
patent: 6028195 (2000-02-01), Cho et al.
patent: 6109269 (2000-08-01), Rise et al.
patent: 6124299 (2000-09-01), Baindur et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6239267 (2001-05-01), Duckworth et al.
patent: 6329395 (2001-12-01), Dugar et al.
patent: 6335180 (2002-01-01), Julius et al.
patent: 6406908 (2002-06-01), McIntyre et al.
patent: 6723730 (2004-04-01), Bakthavatchalam et al.
patent: 2003/0153596 (2003-08-01), Suh et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2003/0158198 (2003-08-01), Lee et al.
patent: 1 014 116 (2000-06-01), None
patent: 1 122 242 (2001-08-01), None
patent: WO 96/21648 (1996-07-01), None
patent: WO 98/00402 (1998-01-01), None
patent: WO 98/25167 (1998-06-01), None
patent: WO 99/07672 (1999-02-01), None
patent: WO 99/37304 (1999-07-01), None
patent: WO 00/52001 (2000-09-01), None
patent: WO 02/05819 (2002-01-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 02/072536 (2002-09-01), None
patent: WO 02/076946 (2002-10-01), None
patent: WO 03/022809 (2003-03-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 03/068749 (2003-08-01), None
Attila T{dot over (o)}th1, Peter M. Blumberg, Zili Chen, and Alan P. Kozikowski, Mol Pharmacol 65:282-291, 2004.
Yun Wang,1 Tamas Szabo, Jacqueline D. Welter, Attila Toth, Richard Tran, Jiyoun Lee,Sang Uk Kang, Young-Ger Suh, Peter M. Blumberg, and Jeewoo Lee, Mol Pharmacol 62:947-956, 2002.
Lopez-Rodriguez, M.L. et al, Mini Reviews in Medicinal Chemistry, vol. 3, 2003, pp. 729-740.
Pomonis, J.D. et al, (J. Exp. Pharm. Exp. Therap., vol. 308, 2003, pp. 397-393.
K. Walker et al., “Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain,” Neuropharmacology 40:1-9, 2000.
A. Dogrul et al., Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR5) antagonist, in experimental neuropathic pain in rats, Neuroscience Letters 292(2):115-118, 2000.
K.W. Foley, “Pain” Cecil Textbook of Medicine, pp. 100-107, 1996.
R.M. Resnick, “Urinary Incontinence,” Lancet 346:94-99, 1995.
A.R. Herzo et al., “Urinary Incontinence: Medical and Psychosocial Aspects,” Annu. Rev. Gerontol. Geriatr. 9:74-119, 1989.
A.W. Wein, “Pharmacology of Incontinence,” Urologic Clinics of North America, 22(3):557-577, 1995.
R.M. Levin et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder,” The Journal of Urology, 128:396-398, 1982.
R.D. Cooke, “Glycopyrrolate in bladder dysfunction,” SA Medical Journal, 63:3, 1983.
R.K. Mirakhur et al., “Glycopyrrolate: pharmacology and clinical use,” Anaesthesia 38:1195-1204, 1983.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 345-350, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 352-355, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 496-500, 1997.
R. Berkow et all., “The Merck Manual of Medical Information,” pp. 525-526, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 528-530, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 530-532, 1997.
R. Berkow et al., “The Merck Manual of Medical Information,” pp. 631-634, 1997.
Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506, 901-915 (J. Hardman and L. Limbird eds., 9thed. 1996).
E. Tatarczynska et al., Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist, British Journal of Pharmaology 132(7):1423-1430, 2001.
P.J.M. Will et al., “Novel allosteric antagonists shed light on mglu5receptors and CNS disorders,” Trends in Pharmacological Sciences, 22(7):331-337, 2001.
K. Ossowska et al., “Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats,” Neuropharmacology 41:413-420, 2001.
C. Chiamulera et al., “Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant rice,” Nature Neuroscience 4(9):873-874, 2001.
Bevan et al., “Vanilloid Receptors: Pivotal Molecules in Nocciception,” Current Opinions in CPNS Investigational Drugs 2(2):178-85 (2000).
Szallash et al., “Vanilloid (Capsaicin) Receptors and Mechanisma,” Pharmacology Reviews 51(2):159-211 (1999).
Wrigglesworth and C. Walpole, “Capsaicin-like Agonists,” Drugs of the Future 23(5):531-8 (1998).
Kwak et al., “A Capsaicin-Receptor Antagonist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance,” Neuroscience 86:619-26 (1998).
Ohkubo et al., “The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinoiceptive Action of Eugenol and Guaiacol,” J. Dent. Res. 76(4):848-51 Apr. 1997.
Pan et al., “Soluble Polymer-Supported Synthesis of Arylpiperazines,” Tett. Lett. 39:9505-8 (1998).
Urban et al., “In Vivo Pharmacology of SDZ 249-665, A Novel, Non-pungent Capsaicin Analogue,” Pain 89:65-74 (2000).
Wu et al., “Multiple Sensory and Functional Effects of Non-phenolic Aminodimethylene Nonivamide: An Approach to Capsaicin Antagonist,” Gen. Pharmac. 27(1):151-8 (1996).
Kyle Donald J.
Qun Sun
Euro-Celtique S.A.
Jones Day
McKenzie Thomas C.
LandOfFree
2-pyridinyl-1-piperazine therapeutic agents useful for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-pyridinyl-1-piperazine therapeutic agents useful for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-pyridinyl-1-piperazine therapeutic agents useful for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3613147